U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Moderately severe hemophilia B

MedGen UID:
1842225
•Concept ID:
C5679575
•
Disease or Syndrome
Synonyms: Moderate congenital F9 deficiency; Moderate congenital factor IX deficiency; Moderate hemophilia B; Moderate hereditary factor IX deficiency disease; moderately severe factor IX deficiency; moderately severe haemophilia type B; moderately severe hemophilia B; moderately severe hemophilia type B
SNOMED CT: Moderate hereditary factor IX deficiency disease (1336092002); Moderate hemophilia B (1336092002)
Modes of inheritance:
X-linked recessive inheritance
MedGen UID:
375779
•Concept ID:
C1845977
•
Finding
Source: Orphanet
A mode of inheritance that is observed for recessive traits related to a gene encoded on the X chromosome. In the context of medical genetics, X-linked recessive disorders manifest in males (who have one copy of the X chromosome and are thus hemizygotes), but generally not in female heterozygotes who have one mutant and one normal allele.
See: This record
X-linked recessive inheritance (Orphanet)
 
Monarch Initiative: MONDO:0015716
Orphanet: ORPHA169796

Definition

A factor activity level >=1 percent of normal and <=5 percent of normal. [from SNOMEDCT_US]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVModerately severe hemophilia B

Professional guidelines

PubMed

Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
Yan S, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Wilson M
J Med Econ 2024 Jan-Dec;27(1):758-765. Epub 2024 Jun 6 doi: 10.1080/13696998.2024.2351762. PMID: 38708771
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G, Coppens M, Pipe SW
Expert Rev Hematol 2023 Jul-Dec;16(12):919-932. Epub 2023 Dec 18 doi: 10.1080/17474086.2023.2276206. PMID: 37882214
Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J, Kim H, Sivamurthy K, Monahan PE, Fries M
Curr Med Res Opin 2023 Feb;39(2):227-237. Epub 2022 Oct 25 doi: 10.1080/03007995.2022.2133492. PMID: 36285399

Recent clinical studies

Etiology

Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G, Coppens M, Pipe SW
Expert Rev Hematol 2023 Jul-Dec;16(12):919-932. Epub 2023 Dec 18 doi: 10.1080/17474086.2023.2276206. PMID: 37882214
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, Dolan G, Reiss U, Phillips M, Riddell A, Peralta MR, Quaye M, Patch DW, Tuddenham E, Dane A, Watissée M, Long A, Nathwani A
N Engl J Med 2022 Jul 21;387(3):237-247. doi: 10.1056/NEJMoa2119913. PMID: 35857660
Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study.
Windyga J, Stasyshyn O, Lissitchkov T, Mamonov V, Serban M, Rusen L, Ploder B, Tangada S
Clin Appl Thromb Hemost 2020 Jan-Dec;26:1076029620950836. doi: 10.1177/1076029620950836. PMID: 32866032Free PMC Article
Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.
Windyga J, Timofeeva M, Stasyshyn O, Mamonov V, Lamas Castellanos JL, Lissitchkov T, Chojnowski K, Chapman M, Pavlova BG, Tangada S
Clin Appl Thromb Hemost 2020 Jan-Dec;26:1076029620946839. doi: 10.1177/1076029620946839. PMID: 32816519Free PMC Article
Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
Korth-Bradley JM, Rendo P, Smith L, Altisent C
Clin Ther 2016 Apr;38(4):936-44. Epub 2016 Mar 8 doi: 10.1016/j.clinthera.2016.02.015. PMID: 26969334

Diagnosis

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
Shapiro AD, Di Paola J, Cohen A, Pasi KJ, Heisel MA, Blanchette VS, Abshire TC, Hoots WK, Lusher JM, Negrier C, Rothschild C, Roth DA
Blood 2005 Jan 15;105(2):518-25. Epub 2004 Sep 21 doi: 10.1182/blood-2004-06-2283. PMID: 15383463

Therapy

Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
Yan S, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Wilson M
J Med Econ 2024 Jan-Dec;27(1):758-765. Epub 2024 Jun 6 doi: 10.1080/13696998.2024.2351762. PMID: 38708771
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G, Coppens M, Pipe SW
Expert Rev Hematol 2023 Jul-Dec;16(12):919-932. Epub 2023 Dec 18 doi: 10.1080/17474086.2023.2276206. PMID: 37882214
Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program.
Laws HJ, Fukutake K, Lopez-Fernandez MF, Li Y, Seifert W, Tagliaferri A
Eur J Haematol 2023 Aug;111(2):293-299. Epub 2023 May 26 doi: 10.1111/ejh.14010. PMID: 37232041
Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J, Kim H, Sivamurthy K, Monahan PE, Fries M
Curr Med Res Opin 2023 Feb;39(2):227-237. Epub 2022 Oct 25 doi: 10.1080/03007995.2022.2133492. PMID: 36285399
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, Dolan G, Reiss U, Phillips M, Riddell A, Peralta MR, Quaye M, Patch DW, Tuddenham E, Dane A, Watissée M, Long A, Nathwani A
N Engl J Med 2022 Jul 21;387(3):237-247. doi: 10.1056/NEJMoa2119913. PMID: 35857660

Prognosis

Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
Yan S, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Wilson M
J Med Econ 2024 Jan-Dec;27(1):758-765. Epub 2024 Jun 6 doi: 10.1080/13696998.2024.2351762. PMID: 38708771
Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J, Kim H, Sivamurthy K, Monahan PE, Fries M
Curr Med Res Opin 2023 Feb;39(2):227-237. Epub 2022 Oct 25 doi: 10.1080/03007995.2022.2133492. PMID: 36285399
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, Dolan G, Reiss U, Phillips M, Riddell A, Peralta MR, Quaye M, Patch DW, Tuddenham E, Dane A, Watissée M, Long A, Nathwani A
N Engl J Med 2022 Jul 21;387(3):237-247. doi: 10.1056/NEJMoa2119913. PMID: 35857660
Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
Korth-Bradley JM, Rendo P, Smith L, Altisent C
Clin Ther 2016 Apr;38(4):936-44. Epub 2016 Mar 8 doi: 10.1016/j.clinthera.2016.02.015. PMID: 26969334

Clinical prediction guides

Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
Yan S, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Wilson M
J Med Econ 2024 Jan-Dec;27(1):758-765. Epub 2024 Jun 6 doi: 10.1080/13696998.2024.2351762. PMID: 38708771
Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J, Kim H, Sivamurthy K, Monahan PE, Fries M
Curr Med Res Opin 2023 Feb;39(2):227-237. Epub 2022 Oct 25 doi: 10.1080/03007995.2022.2133492. PMID: 36285399
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, Dolan G, Reiss U, Phillips M, Riddell A, Peralta MR, Quaye M, Patch DW, Tuddenham E, Dane A, Watissée M, Long A, Nathwani A
N Engl J Med 2022 Jul 21;387(3):237-247. doi: 10.1056/NEJMoa2119913. PMID: 35857660
Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.
Windyga J, Timofeeva M, Stasyshyn O, Mamonov V, Lamas Castellanos JL, Lissitchkov T, Chojnowski K, Chapman M, Pavlova BG, Tangada S
Clin Appl Thromb Hemost 2020 Jan-Dec;26:1076029620946839. doi: 10.1177/1076029620946839. PMID: 32816519Free PMC Article
Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
Korth-Bradley JM, Rendo P, Smith L, Altisent C
Clin Ther 2016 Apr;38(4):936-44. Epub 2016 Mar 8 doi: 10.1016/j.clinthera.2016.02.015. PMID: 26969334

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Reviews

    Related information

    • GTR
      Related information in GTR
    • GTR(Clinical)
      Clinical tests in GTR
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...